Business
£4.8m contracts awarded
Abingdon Health plc has secured approximately £4.8 million in new contracts with a US-based customer for the development and scaled manufacturing of multiplex quantitative lateral flow assay systems. These agreements, spanning roughly 27 months, encompass full programme management, regulatory processes, and analytical and clinical performance services, leveraging Abingdon's integrated CDMO/CRO capabilities across its UK and US facilities. The contracts represent a significant validation of the company's end-to-end service offering for complex diagnostic devices. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n \n\n \nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\n \n£4.8m contracts awarded for development of multiplex lateral flow systems\n \nYork, U.K. 30 March 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it has been awarded a series of significant contracts with a USA-based customer to develop, and scale up to manufacture several multiplex quantitative lateral flow assay systems measuring multiple biomarkers simultaneously in human samples. The contracts include full programme management, the management of regulatory processes, and analytical and clinical performance services.\n \nThe contracts have a total value of approximately £4.8 million based on the agreed scope of work and will be delivered over a circa 27-month period commencing immediately. These contracts will be executed via a series of work packages based on agreed milestones, with potential further scope beyond that period including appointment as legal manufacturer. The contracts represent an important validation of Abingdon Health's full programme management CDMO service which offers development from feasibility and initial regulatory pathway provision through to product manufacture and multi-territory regulatory approvals.\n \nThe programmes of work will leverage the Group's established and growing capabilities in lateral flow test development and manufacture in its York, UK and Madison, Wisconsin, USA facilities. In addition, the programmes will utilise its regulatory services companies, CS Lifesciences and IVDeology, as well as analytical and clinical performance evaluation services provided by Abingdon Analytical at its Doncaster, UK facilities. It underscores Abingdon Health's position as a leading provider of integrated CDMO/CRO services for rapid diagnostic tests and med-tech.\n \nDr Chris Hand,...